Por medio del Acuerdo de , la Comisión de Regulación en Salud – CRES-, introdujo ajustes al Acuerdo , por medio del cual se. acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. P P 11 1 P(|racu|ra |loslalo) 15 rd de oase lao|ela o cápsu|a. P Z0 1 0u|r|ra d|c|o(r|d(alo rd/2 rL so|uc|ór |rveclao|e. P 10 1 0u|r|ra.

Author: Akicage Junos
Country: Togo
Language: English (Spanish)
Genre: Environment
Published (Last): 23 January 2010
Pages: 448
PDF File Size: 19.68 Mb
ePub File Size: 12.7 Mb
ISBN: 309-8-37892-511-3
Downloads: 41703
Price: Free* [*Free Regsitration Required]
Uploader: Kazshura

Statin treatment for primary prevention of vascular disease: Table 3 presents the results of the bivariate analysis that compared a subgroup of patients with controlled dyslipidemia with a subgroup of patients with uncontrolled 0229 belonging to risk group 1. Fitzner K, Heckinger E.

Effects of Quality Improvement Strategies for type 2 diabetes on glycemic control. J Manag Care Pharm. The cost effectiveness of statin therapies in Spain inafter the introduction of generics and reference prices.

A significant association was found between the rate of total-C control and the following variables: Eur J Cardiovasc Prev Rehabil. When life expectancy and income increase among a population, so does the prevalence of noncommunicable diseases NCDssuch as hypertension, obesity, dyslipidemia, and diabetes.

Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: There is also evidence that earlier interventions produce more cost-effective results In cases where the target LDL-C level was not being met, and if all patients crea considered to have complied with the adjustments, then therapy modifications were insufficient 19, Patient information was reviewed systematically by a physician using a designated data collection form to obtain the following study variables from the medical records: In risk group 2, the average dose of lovastatin was lower in the controlled patients than in the uncontrolled 62 vs.


Measurements of LDL-C at fres initiation were found for patients Colombia has adopted an essential drugs list into the Plan Obligatorio de Salud Mandatory Health Plan, POS ; initially it included three generic agents for dyslipidemia management: Additionally, differences between the initial mean: In cases Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men.

Acuerdo by Yennǐfer Morales Velez on Prezi

However, despite the guidelines and the evidence of treatment benefits and safety, numerous studies have shown that a small proportion of dyslipidemic patients regularly use lipid-lowering drugs, and an even smaller percentage of people treated have serum cholesterol levels within the range recommended by international protocols It is disconcerting that only On average, there was a 4.

Primatesta P, Poulter RN.

Subjects were predominantly female Prescription patterns for antilipidemic drugs in a group of Colombian patients. Ministry of Health, Colombia.

acuerdo 029 de 2011 cres pdf

A statistically significant association was found between the rate of dyslipidemia control and the following variables: Detection, evaluation, and treatment of high blood cholesterol in adults.


The above findings support increasing the dose of the lipid-lowering therapy based on clearly defined objectives 16, Conversely, it is recommended that insurance companies monitor treatment effectiveness, and even adjust the medication in question, or recommend that the clinician do so ReadCube Visualizar o texto. According to the results of the present study, the prevalent characteristics of patients in the high cardiovascular risk group with uncontrolled dyslipidemia are two or more of following variables: Eur J Gen Pract.

In the patients comprising risk group 1, To provide physicians with tools for dyslipidemia detection, assessment, and treatment, several panels of experts have developed clinical guidelines 7, 8.

Cardiovascular disease and lipids. Additionally, the presence of comorbidities, such as diabetes mellitus, which contribute to cardiovascular risk, should be evaluated for treatment with the drug of choice and at the appropriate dose Dislipidemias; anticolesterolemiantes; enfermedades cardiovasculares; lovastatina; gemfibrozilo; Colombia. The main comorbidities and co-medications used to manage these and other risk factors are shown in Table 1.

Manuscript received on 14 May Study design and sample.